Effect of empagliflozin on lipid metabolism in patient with type 2 diabetes mellitus and obesity

• Alina P. Misharova

Abstract

Currently, the study of the non-glycemic effects of drugs from the group of sodium-glucose cotransporter type 2 inhibitors is ongoing. This study examined lipid metabolism in 39 patients with type 2 diabetes mellitus and obesity. 2 groups of patients were randomized by type of treatment. The main group (n=17) taking metformin + empagliflozin was compared with the control group taking metformin (n=22). According to the results in the combination group, we found statistically significant increase in the level of adiponectin and positive trend in some indicators of lipid metabolism.

Keywords:diabetes mellitus; obesity; adiponectin; lipid metabolism; empagliflozin

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)